Lipoprotein Lp(a) excess and coronary heart disease

Archives of Internal Medicine

Volumn 157, Issue 11, 1997, Pages 1170-1176

  Stein, James H ^a   Rosenson, Robert S ^b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEZAFIBRATE; CLOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

CORONARY ARTERY ATHEROSCLEROSIS; ESTROGEN THERAPY; EVIDENCE BASED MEDICINE; FIBRINOLYSIS; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPOPROTEINEMIA; ISCHEMIC HEART DISEASE; PRIORITY JOURNAL; REVIEW; SCREENING; THROMBOSIS; TREATMENT PLANNING;

EID: 0030987764     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.157.11.1170     Document Type: Review

References (119)

1. Bostom AG, Cupples LA, Jenner JL, et al. Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger: a prospective study. JAMA 1996;27:544-546.
2. Bostom AG, Gagnon DR, Cupples LA, et al. A prospective investigation of elevated lipoprotein(a) detected by electrophoresis and cardiovascular disease in women: the Framingham Heart Study. Circulation. 1994;90:1688-1695.
3. Schaefer EJ, Lamon-Fava S, Jenner JL, et al. Lipoprotein(a) levels and risk of coronary heart disease in men. JAMA. 1994;271:999-1003.
4. Cremer P, Nagel D, Labrot B, et al. Lipoprotein Lp(a) as predictor of myocardial infarction in comparison to fibrinogen, LDL cholesterol and other risk factors: results from the prospective Göttingen Risk Incidence and Prevalence Study (GRIPS). Eur J Clin Invest. 1994;24:444-453.
5. Wald NJ, Law M, Watt HC, et al. Apolipoproteins and ischaemic heart disease: implications for screening. Lancet. 1994;343:75-79.
6. Rosengren A, Wilhelmsen L, Eriksson E, Risberg B, Wedel H. Lipoprotein(a) and coronary heart disease: a prospective case-control study in a general population sample of middle aged men. BMJ. 1990;301:1248-1251.
7. Sigurdsson G, Baldursdottir A, Sigvaldason H, Agnarsson U, Thorgeirsson G, Sigfusson N. Predictive value of apolipoproteins in a prospective survey of coronary artery disease in men. Am J Cardiol. 1992;69:1251-1254.
8. Genest JJ Jr, Martin-Munley SS, McNamara JR, et al. Familial lipoprotein disorders in patients with premature coronary artery disease. Circulation. 1992;85:2025-2033.
9. Rosenson RS. Beyond low-density lipoprotein cholesterol: a perspective on low high-density lipoprotein disorders and Lp(a) lipoprotein excess. Arch Intern Med. 1996;156:1278-1284.
10. Gaubatz JW, Heideman C, Gotto AM Jr, Morrisett JD, Dahlen GM. Isolation and characterization of the two major apoproteins in human lipoprotein(a). J Biol Chem. 1983;258:4582-4589.
11. Utermann G, Weber W. Protein composition of Lp(a) lipoprotein from human plasma. FEBS Lett. 1983;154:357-361.
12. Eaton DL, Fless GM, Kohr WJ, et al. Partial amino acid sequence of apolipoprotein(a) shows that it is homologous to plasminogen. Proc Natl Acad Sci U S A. 1987;84:3224-3228.
13. McLean JW, Tomlinson JE, Kuang W-J, et al. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature. 1987; 330:132-137.
14. Drayna DT, Hegele RA, Hass PE, et al. Genetic linkage between lipoprotein(a) phenotype and a DNA polymorphism in the plasminogen gene Genomics. 1988;3:230-236.
15. Lindahl G, Gersdorf W, Menzel HJ, et al. The gene for the Lp(a) specific glycoprotein is closely linked to the gene for plasminogen on chromosome 6. Hum Genet. 1989;81:149-152.
16. Frank SL, Klisak I, Sparkes RS, et al. The apolipoprotein(a) gene resides on human chromosome 6q26-27, in close proximity to the homologous gene for plasminogen. Hum Genet. 1988;79:352-356.
17. Brown MS, Goldstein JL. Plasma lipoproteins: teaching old dogmas new tricks. Nature. 1987; 320:113-114.
18. Miles LA, Plow EF. Lp(a): an interloper into the fibrinolytic system? Thromb Haemost. 1990; 63:331-335.
19. von Hodenberg E, Kreuzer J, Hautmann M, Nordt T, Kübler W, Bode C. Effects of lipoprotein(a) on success rate of thrombolytic therapy in acute myocardial infarction. Am J Cardiol. 1991;67: 1349-1353.
20. Moliterno DJ, Lange RA, Meidell RS, et al. Relation of plasma lipoprotein(a) to infarct artery patency in survivors of myocardial infarction. Circulation. 1993;88:935-940.
21. Lawn RM. The structure and evolution of apolipoprotein(a). In: Scanu AM, moderator. Lipoprotein(a) and atherosclerosis. Ann Intern Med. 1991;115:209-218.
22. Wade DP. Lipoprotein(a). Curr Opin Lipidol. 1993; 4:244-249.
23. Walton KW, Hitchens J, Magnani AL, Khan M. A study of methods of identification and estimation of Lp(a) lipoprotein and of its significance in health, hyperlipidaemia, and atherosclerosis. Atherosclerosis. 1974;20:323-346.
24. Stenman S, von Smitten K, Vaheri A. Fibronectin and atherosclerosis. Acta Med Scand Suppl. 1980;642:165-170.
25. Salonen E-M, Jauhiainen M, Zardi L, Vaheri A, Ehnholm C. Lipoprotein(a) binds to fibronectin and has serine proteinase activity capable of cleaving it. EMBO J. 1989;8:4035-4040.
26. Rath M, Niendorf A, Reblin T, Dietel M, Krebber H-J, Beisiegel U. Detection and quantification of lipoprotein(a) in the arterial wall of 107 coronary bypass patients. Arteriosclerosis. 1989; 9:579-592.
27. Hajjar KA, Gavish D, Breslow JL, Nachman RL. Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis. Nature. 1989;339:303-305.
28. Gushing GL, Gaubatz JW, Nava ML, et al. Quantitation and localization of apolipoproteins [a] and B in coronary artery bypass vein grafts resected at re-operation. Arteriosclerosis. 1989; 9:593-603.
29. Naruszewicz M, Selinger E, Davignan J. Oxidative modification of lipoprotein(a) and the effect of β-carotene. Metabolism. 1992;41:1215-1224.
30. Hansen PR, Kharazmi A, Jauhianen M, Enholm C. Induction of oxygen free radical generation in human monocytes by lipoprotein(a). Eur J Clin Invest. 1994;24:497-499.
31. Sorenson KE, Celermajer DS, Georgakopoulos D, Hatcher G, Betteridge DJ, Deanfield JE. Impairment of endothelium-dependent dilation is an early event in children with familial hypercholesterolemia and is related to the lipoprotein(a) level. J Clin Invest. 1994;93:50-57.
32. Lackner C, Boerwinkle E, Leffert CC, Rahmig T, Hobbs HH. Molecular basis of apolipoprotein(a) isoform size heterogeneity as revealed by pulsed-field gel electrophoresis. J Clin Invest. 1991;87:2153-2161.
33. Boerwinkle E, Leffert CC, Lin J, Lackner C, Chiesa G, Hobbs HH. Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. J Clin Invest. 1992;90:52-60.
34. Sandholzer C, Hallman DM, Saha N, et al. Effects of the apolipoprotein(a) size polymorphism on the lipoprotein(a) concentration in 7 ethnic groups. Hum Genet. 1991;86:607-614.
35. Maeda S, Abe A, Seishima M, Makino K, Noma A, Kawade M. Transient changes of serum lipoprotein(a) as an acute phase protein. Atherosclerosis. 1989;78:145-150.
36. Slunga L, Johnson O, Dahlen GH, Eriksson S. Lipoprotein(a) and acute-phase proteins in acute myocardial infarction. Scand J Clin Lab Invest. 1992;52:95-101.
37. Brunelli C, Spallarossa P, Bertolini S, et al. Lipoprotein(a) is increased in acute coronary syndromes (unstable angina pectoris and myocardial infarction), but it is not predictive of the severity of coronary lesions. Clin Cardiol. 1995; 18:526-529.
38. Oshima S, Uchida K, Yasu T, Uno K, Nonogi M, Haze K. Transient increase of plasma lipoprotein(a) in patients with unstable angina pectoris: does lipoprotein(a) alter fibrinolysis. Arterioscler Thromb. 1991;11:1772-1777.
39. Zechner R, Desoye G, Schweditsen MO, Pfeiffer KP, Kostner DM. Fluctuations of plasma lipoprotein-a concentrations during pregnancy and post-partum. Metabolism. 1986;35:333.
40. Wright LC, Sullivan DR, Muller M, Dyne M, Tattersall MHN, Mountford CE. Elevated apolipoprotein(a) levels in cancer patients. Int J Cancer. 1989;93:241-244.
41. Cressman MD, Heyka RJ, Paganini EP, O'Neil J, Skibinski CI, Hoff HF. Lipoprotein(a) is an independent risk factor for cardiovascular disease in hemodialysis patients. Circulation. 1992; 86:475-482.
42. Dieplinger H, Lackner C, Kronenberg F, et al. Elevated plasma concentrations of lipoprotein(a) in patients with end-stage renal disease are not related to the size polymorphism of apolipoprotein(a). J Clin Invest. 1993;91:397-401.
43. Wanner C, Rader D, Bartens W, et al. Elevated plasma lipoprotein(a) in patients with the nephrotic syndrome. Ann Intern Med. 1993;119: 263-269.
44. Stenvinkel P, Berglund L, Heimburger O, Pettersson E, Alvestrand A. Lipoprotein(a) in nephrotic syndrome. Kidney Int. 1993;44:1116-1123.
45. Haffner SM, Tuttle KR, Rainwater DL. Lack of change of lipoprotein(a) concentration with improved glycemic control in subjects with type II diabetes. Metabolism. 1992;41:116-120.
46. Ramirez LC, Arauz-Pacheco C, Lackner C, Albright G, Adams BV, Raskin P. Lipoprotein(a) levels in diabetes mellitus: relationship to metabolic control. Ann Intern Med. 1992;117:42-47.
47. Farrer M, Game FL, Albers CJ, et al. Association between impaired glucose tolerance and circulating concentration of Lp(a) lipoprotein in relation to coronary heart disease. BMJ. 1993; 307:832-836.
48. Velho G, Erlich D, Turpin E, et al. Lipoprotein(a) in diabetic patients and normoglycemic relatives in familial NIDDM. Diabetes Care. 1993; 16:742-747.
49. Maser RE, Usher D, Becker DJ, Drash AL, Kuller LH, Orchard TJ. Lipoprotein(a) concentration shows little relationship to IDDM complications in the Pittsburgh epidemiology of diabetes complications study cohort. Diabetes Care. 1993;16:755-758.
50. Spandrio S, Sleiman I, Scalvini T, et al. Lipoprotein(a) in thyroid dysfunction before and after treatment. Horm Metab Res. 1993;25:586-589.
51. Henriksson P, Angelin B, Berglund L. Hormonal regulation of serum Lp(a) levels: opposite effects after estrogen treatment and orchidectomy in males with prostate carcinoma. J Clin Invest. 1992;89:1166-1171.
52. Albers JJ, Taggart HM, Applebaum-Bowden D, Haffner S, Chestnutt CH III, Hazzard WR. Reduction of lecithin-cholesterol acyltransferase, apolipoprotein d and the Lp(a) lipoprotein with the anabolic steroid stanozolol. Biochim Biophys Acta. 1984;795:293-296.
53. Dahlen GH, Ericson C, Furberg C, Lundkrist L, Svärsudd K. Angina of effort and an extra prebeta lipoprotein fraction. Acta Med Scand Suppl. 1972;531:11-15.
54. 1-lipoprotein in Swedish middle-aged males and in patients with coronary heart disease. Clin Genet. 1975;7:334-341.
55. Superko HR. Beyond LDL cholesterol reduction. Circulation. 1996;94:2351-2354.
56. Albers JJ, Adolphson JL, Hazzard WR. Radioimmunoassay of human plasma Lp(a) lipoprotein. J Lipid Res. 1977;18:331-338.
57. Berg K, Dahlén G, Borresen A-L. Lp(a) phenotypes, other lipoprotein parameters, and a family history of coronary heart disease in middle-aged males. Clin Genet. 1979;16:347-352.
58. Rhoads GG, Dahlen G, Berg K, Morton NE, Dannenberg AL. Lp(a) lipoprotein as a risk factor for myocardial infarction. JAMA. 1986;256: 2540-2544.
59. Dahlen GH, Guyton JR, Attar M, Farmer JA, Kautz JA, Gotto AM Jr. Association of levels of lipoprotein Lp(a) plasma lipids, and other lipoproteins with coronary artery disease documented by angiography. Circulation. 1986;74: 758-765.
60. Sandkamp M, Funke H, Schulte H, Köhler E, Assmann G. Lipoprotein(a) is an independent risk factor for myocardial infarction at a young age. Clin Chem. 1990;36:20-23.
61. Durrington PN, Ishola M, Hunt L, Arrol S, Bhatnagar D. Apolipoproteins(a), AI, and B and parental history in men with early onset ischaemic heart disease. Lancet 1988;1:1070-1073.
62. Genest JJ Jr, Jenner JL, McNamara JR, et al. Prevalence of lipoprotein(a) [Lp(a)] excess in coronary artery disease. Am J Cardiol. 1991; 67:1039-1045.
63. Labeur C, De Bacquer D, De Backer G, et al. Plasma lipoprotein(a) values and severity of coronary artery disease in a large population of patients undergoing coronary angiography. Clin Chem. 1992;38:2261-2266.
64. Genest JJ Jr, McNamara JR, Ordovas JM, et al. Lipoprotein cholesterol, apolipoprotein A-I and B and lipoprotein(a) abnormalities in men with premature coronary artery disease. J Am Coll Cardiol. 1992;19:792-802.
65. Parra HJ, Arveiler D, Evans AE, et al. A case-control study of lipoprotein particles in two populations at contrasting risk for coronary heart disease: the ECTIM study. Arterioscler Thromb. 1992;12:701-707.
66. Budde T, Fechtrup C, Bösenberg E, et al. Plasma Lp(a) lipoprotein levels correlate with number, severity, and length-extension of coronary lesions in male patients undergoing coronary artenography for clinically suspected coronary atherosclerosis. Arterioscler Thromb. 1994;14: 1730-1736.
67. Farrer M, Game FL, Albers CJ, et al. Coronary artery disease is associated with increased lipoprotein(a) concentrations independent of the size of circulating apolipoprotein(a) isoforms. Arterioscler Thromb. 1994;14:1272-1283.
68. Ridker PM, Hennekens CH, Meir MJ, Stampfer MJ. A prospective study of lipoprotein(a) and the risk of myocardial infarction. JAMA. 1993; 270:2195-2199.
69. Jauhiainen M, Koskinen P, Ehnholm C, et al. Lipoprotein(a) and coronary heart disease risk: a nested case-control study of the Helsinki Heart Study participants. Atherosclerosis. 1991;89: 59-67.
70. Coleman MP, Key TJA, Wang DY, et al. A prospective study of obesity, lipids, apolipoproteins and ischaemic heart disease in women. Atherosclerosis. 1992;92:177-185.
71. Craig WY, Poulin SE, Forster NR, Neveux LM, Wald NJU, Ledve TB. Effect of sample storage on the assay of lipoprotein(a) by commercially available radial immunodiffusion and enzyme-linked immunosorbent assay kits. Clin Chem. 1992;38:550-553.
72. Wiklund O, Angelin B, Olofsson S-O, et al. Apolipoprotein(a) and ischaemic heart disease in familial hypercholesterolaemia. Lancet. 1990; 335:1360-1363.
73. Seed M, Hoppichler F, Reaveley D, et al. Relation of serum lipoprotein(a) concentration and apolipoprotein(a) phenotype to coronary heart disease in patients with familial hypercholesterolemia. N Engl J Med. 1990;322:1494-1498.
74. Barbir M, Kushwaha S, Hunt B, et al. Lipoprotein(a) and accelerated coronary artery disease in cardiac transplant recipients. Lancet. 1992;340:1500-1502.
75. Desmarais RL, Sarembock IJ, Ayers CR, Vernon SM, Powers ER, Gimple LW. Elevated serum lipoprotein(a) is a risk factor for clinical recurrence after coronary balloon angioplasty. Circulation. 1995;91:1403-1409.
76. Cooke T, Sheahan R, Foley D, et al. Lipoprotein(a) in restenosis after percutaneous transluminal coronary angioplasty and coronary artery disease. Circulation. 1994;89:1593-1598.
77. Daida H, Lee YJ, Yokoi H, et al, and the Low-Density Lipoprotein Apheresis Angioplasty Restenosis Trial (L-ART) Group. Prevention of restenosis after percutaneous transluminal coronary angioplasty by reducing lipoprotein(a) levels with low-density lipoprotein apheresis. Am J Cardiol. 1994;73:1037-1040.
78. Hoff HF, Beck GJ, Skibinski CI, et al. Serum Lp(a) level as a predictor of vein graft stenosis after coronary artery bypass surgery in patients. Circulation. 1988;77:1238-1244.
79. Hellsten G, Boman K, Hallmans G, Dahlén G. Lipids and endurance physical activity. Atherosclerosis. 1989;75:93-94.
80. Hornstra G, van Houwelingen AC, Kester ADM, Sundram K. A palm oil-enriched diet lowers serum lipoprotein(a) in normocholesterolemic volunteers. Atherosclerosis. 1991;90:91-93.
81. Brewer HB. Effectiveness of diet and drugs in the treatment of patients with elevated Lp(a) level. In: Scanu AM, ed. Lipoprotein(a). Orlando, Fla: Academic Press Inc; 1990:211.
82. Herrmann W, Biermann J, Kostner GM. Comparison of effects of N-3 to N-6 fatty acids on serum level of lipoprotein(a) in patients with coronary artery disease. Am J Cardiol. 1995;76:459-462.
83. Rader DJ, Brewer HB. Lipoprotein(a): clinical approach to a unique atherogenic lipoprotein JAMA. 1992;267:1109-1112.
84. Vessby B, Kostner G, Lithell H, Thomis J. Diverging effects of cholestyramine on apolipoprotein B and lipoprotein Lp(a). Atherosclerosis. 1982;44:61-71.
85. Leren TP, Hjermann I, Berg K, Leren P, Foss OP, Viksmoen L. Effects of lovastatin alone and in combination with cholestyramine on serum lipids and apolipoproteins in heterozygotes for familial hypercholesterolemia. Atherosclerosis. 1988;73:135-141.
86. Leren TP, Hjermann I, Foss OP, Leren P, Berg K. Long-term effect of lovastatin alone and in combination with cholestyramine on lipoprofein(a) level in familial hypercholesterolemic subjects. Clin Invest. 1992;70:711-718.
87. Jacob BG, Richter WO, Schwandt P. Lovastatin, pravastatin, and serum lipoprotein(a). Ann Intern Med. 1990;112:713-714.
88. Thompson GR, Maher VMG, Matthews S, et al. Familial Hypercholesterolaemia Regression Study: a randomised trial of low-density-lipoprotein apheresis. Lancet. 1995;345:811-816.
89. Perez-Jimenez F, Hidalgo L, Zambrana JL, et al. Comparison of lovastatin and bezafibrate on lipoprotein(a) plasma levels in cardiac transplant recipients. Am J Cardiol. 1995;75:648-650.
90. Kostner GM, Gavish D, Leopold B, Bolzano K, Weintraub MS, Breslow JL. HMG CoA reductase inhibitors lower LDL cholesterol without reducing Lp(a) levels. Circulation. 1989;80: 1313-1319.
91. Jürgens G, Ashy A, Zenker G. Raised serum lipoprotein during treatment with lovastatin. Lancet. 1989;1:911-912.
92. Slunga L, Johnson O, Dahlén GH. Changes in Lp(a) lipoprotein levels during the treatment of hypercholesterolaemia with simvastatin. Eur J Clin Pharmacol. 1992;43:369-373.
93. Haffner S, Orchard T, Stein E, Schmidt D, LaBelle P. Effect of simvastatin on Lp(a) concentrations. Clin Cardiol. 1995;18:261-267.
94. Klausen IC, Gerdes LU, Meinertz H, Hansen FA, Faergeman O. Apolipoprotein(a) polymorphism predicts the increase of Lp(a) by pravastatin in patients with familial hypercholesterolaemia treated with bile acid sequestration. Eur J Clin Invest. 1993;23:240-245.
95. Hunninghake DB, Stein EA, Mellies MJ. Effects of one year of treatment with pravastatin, an HMG-CoA reductase inhibitor, on lipoprotein (a). J Clin Pnarmacol. 1993;33:574-580.
96. Noma A, Maeda S, Okuno M, Abe A, Muto Y. Reduction of serum lipoprotein(a) levels in hyperlipidaemic patients with α-tocopheryl nicotinate. Atherosclerosis. 1990;84:213-217.
97. Naruszewicz M, Selinger E, Dufour R, Davignon J. Probucol protects lipoprotein(a) against oxidative modification. Metabolism. 1992;41:1225-1228.
98. Børresen A-L, Berg K, Dahlén G, Gillnäs T, Ericson C. The effect of gemfibrozil on human serum apolipoproteins and on serum reserve cholesterol binding capacity (SRCBC). Artery. 1981;9:77-86.
99. Kostner GM, Klein G, Krempler F. Can serum Lp(a) concentrations be lowered by drugs and/or diet? In: Carlson LA, Olsson AG, eds. Treatment of Hyperlipoproteinemia. New York, NY: Raven Press; 1984:151-156.
100. Bimmermann A, Boerschmann C, Schwartzkopff W, Von Baeyer H, Schleicher J. Effective therapeutic measures for reducing lipoprotein(a) in patients with dyslipidemia: lipoprotein(a) reduction with sustained-release bezafibrate. Curr Ther Res. 1991;49:635-643.
101. Maggi FM, Biasi GM, Catapano AL. Reduction of Lp(a) plasma levels by bezafibrate. Atherosclerosis. 1993;100:127-128.
102. Soma MR, Osnago-Gadda I, Paoletti R, et al. The lowering of lipoprotein(a) induced by estrogen plus progesterone replacement therapy in postmenopausal women. Arch Intern Med. 1993;153:1462-1468.
103. Sacks FM, McPherson R, Walsh BW. Effect of postmenopausal estrogen replacement on plasma Lp(a) lipoprotein concentrations. Arch Intern Med. 1994;154:1106-1110.
104. Kim CJ, Jang HC, Cho DH, Min YK. Effects of hormone replacement therapy on lipoprotein(a) and lipids in postmenopausal women. Arterioscler Thromb. 1994;14:275-281.
105. Kim CJ, Min YK, Ryu WS, Kwak JW, Ryoo UH. Effect of hormone replacement therapy on lipoprotein(a) and lipid levels in postmenopausal women: influence of various progestogens and duration of therapy. Arch Intern Med. 1996;156:1693-1700.
106. Shewmon DA, Stock JL, Rosen CJ, et al. Tamoxifen and estrogen lower circulating lipoprotein(a) concentrations in healthy postmenopausal women. Arterioscler Thromb. 1994;14: 1586-1593.
107. Haines C, Chung T, Chang A, Masarei J, Tomlinson B, Wong E. Effect of oral estradiol on Lp(a) and other lipoproteins in postmenopausal women. Arch Intern Med. 1996;156: 866-872.
108. Carlson LA, Hamsten A, Asplund A. Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid. J Intern Med. 1989;226: 271-276.
109. Seed M, O'Connor B, Perombelon N, O'Donnell M, Reaveley D, Knight BL. The effect of nicotinic acid and acipimox on lipoprotein(a) concentration and turnover. Atherosclerosis. 1993; 101:61-68.
110. Gurakar A, Hoeg JM, Kostner G, Papadopoulos MM, Brewer HB Jr. Levels of lipoprotein Lp(a) decline with neomycin and niacin treatment. Atherosclerosis. 1985;57:293-301.
111. Koizumi J, Koizumi I, Uno Y, et al. Reduction of lipoprotein(a) by LDL apheresis using a dextran sulphate cellulose column in patients with familial hypercholesterolemia. Atherosclerosis. 1993;110:65-74.
112. Rader DJ, Hoeg JM, Brewer HB Jr. Quantitation of plasma apolipoproteins in the primary and secondary prevention of coronary artery disease. Ann Intern Med. 1994;120:1012-1025.
113. Keilani T, Schlueter WA, Levin ML, Batlle DC. Improvement of lipid abnormalities associated with proteinuria using fosinopril, and angiotensin-converting enzyme inhibitor. Ann Intern Med. 1993;118:246-254.
114. Gavish D, Breslow JL. Lipoprotein(a) reduction by N-acetylcysteine. Lancet. 1991;337:203-204.
115. Kroon AA, Demacker PNM, Stalenhoef AFH. N-acetylcysteine and serum concentrations of lipoprotein(a). J Intern Med. 1991;230: 519-526.
116. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary artery disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
117. Sacks PM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001-1009.
118. Shepherd J, Coffe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:1301-1307.
119. Maher VMG, Brown BG. Lipoprotein(a) and coronary heart disease. Curr Opin Lipidol. 1995;6: 229-235.